|
Mar 22
|
Gilead Sciences Announces Completion of Acquisition of CymaBay
|
|
Mar 11
|
Investing in CymaBay Therapeutics (NASDAQ:CBAY) three years ago would have delivered you a 540% gain
|
|
Mar 4
|
CymaBay Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis
|
|
Feb 21
|
The New England Journal of Medicine Publishes Positive Phase 3 RESPONSE Data of CymaBay's Seladelpar in Primary Biliary Cholangitis
|
|
Jan 23
|
Insider Sell: CymaBay Therapeutics Inc President of R&D Charles Mcwherter Sells 18,403 Shares
|
|
Jan 12
|
Director Janet Dorling Sells 6,000 Shares of CymaBay Therapeutics Inc (CBAY)
|
|
Jan 2
|
CymaBay Therapeutics to Present at the 42nd Annual JP Morgan Healthcare Conference 2024
|
|
Dec 28
|
Why CymaBay Morphed From Dollar Stock To Biotech Rocket
|
|
Dec 20
|
Industry Analysts Just Upgraded Their CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Revenue Forecasts By 32%
|
|
Dec 19
|
Insider Sell Alert: CymaBay Therapeutics Inc's President of R&D Charles Mcwherter Sells ...
|
|
Dec 15
|
CymaBay Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis
|
|
Dec 1
|
Top Stocks for December 2023
|
|
Nov 8
|
Does CymaBay Therapeutics Inc. (CBAY) Have the Potential to Rally 45.99% as Wall Street Analysts Expect?
|
|
Nov 7
|
CymaBay Reports Third Quarter and Nine Months Ended September 30, 2023 Financial Results and Provides Corporate Update
|
|
Nov 6
|
CymaBay Therapeutics to Present at Upcoming Investment Conferences
|
|
Oct 26
|
Are Medical Stocks Lagging Apyx Medical (APYX) This Year?
|
|
Oct 25
|
CymaBay Therapeutics Inc. (CBAY) is on the Move, Here's Why the Trend Could be Sustainable
|
|
Sep 12
|
Why CymaBay Therapeutics Stock Triumphed Again on Tuesday
|
|
Sep 12
|
CymaBay Announces Pricing of Upsized $225 Million Public Offering of Common Stock and Pre-Funded Warrants
|
|
Sep 11
|
Why CymaBay Therapeutics Stock Popped Again Today
|